Replies to post #55314 on Ariad Pharmaceuticals Inc fka ARIA

[micanwait]

Thanks Sik. One of the most informative posts ever.

Everything you ever wanted to know about pona.
Clearly, this is why Denner buys as much Ariad stock as he can.

[LUMA14]

Great article, very objective and finally very positiv to the potential of Ponatinib!

Download of the full article is free of charge!

Great find. Thanks.

[STOCKSEEK]

Great post... Shared it at StockTwits with credit to you.

Great DD

Thx
SS

[micanwait]

Regarding the cure v. treatment issue, there is an interesting discussion... last paragraph of pg.250 on the issue of discontinuing therapy.

".. patients on ponatanib may be more likely to successfully discontinue treatment than those taking imatinib."

[oldchemist4]

Nice find, and an unusually readable paper. The group writing is taking the position that pona would be best as part of a combo therapy; from the last page

"The toxicity profile of ponatinib, however, precludes its use alone as a frontline agent.48 To circumvent this unwanted toxicity, one possibility may include using ponatinib in combination with other therapeutic agents to allow for dose-lowering of ponatinib."


Dose-lowering is not new news, and their objective and positive view of the drug generally is gratifying. One quote (on page 244) in particular;

"However, in nearly one-third of patients, first-line TKI treatment will eventually become ineffective, forcing patients to start on another TKI.12 Most patients will convert to either nilotinib or dasatinib. However, for some patients, especially those possessing the T315I kinase domain mutation, ponatinib (Iclusig®) will be the ideal TKI."